Skip to content
Saturday 5 September 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,831.09
0.00%
DAX
26,046.40
+0.17%
CAC 40
8,278.77
-0.09%
STOXX 50
6,392.93
+0.16%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 07 January 2015 5:47 am

Silicon Valley was right to invest in DNA: Facebook and Google-backed personal genetics business strikes $10m deal with Genentech

By: Sarah Spickernell

Add as a preferred source on Google

Facebook and Google will be pleased about their decision to invest in personal genetics business 23andMe.
 
The firm, which sells DNA testing kits to individual customers for $99 (£65) each, has secured a major deal with Genentech – a subsidiary of Roche. 
 
According to Forbes, 23andMe is receiving an upfront payment from Genentech of $10m, with further payments of as much as $50m to follow. 
 
The biotech firm was attracted to 23andMe because of the access the deal will provide to a whole wealth of personal DNA data: nearly all of 23andMe's 800,000 customers agreed to have their sequenced genome donated for third party research.  
 
In the case of Genentech, the data will be used to study Parkinson's disease – a hereditary disorder which causes the central nervous system to stop working properly. 12,000 Parkinson's patients and 1,300 of their family members have signed up to 23andMe. 

ATTRACTING DEALS ACROSS THE SECTOR

Genetech is not the only firm to have a keen interest in the DNA database – 23andMe has signed nine other deals with large biotech and pharmaceutical companies. In fact, the company has been collaborating with businesses in the sector since it was founded in 2006. 
 
Last year, it signed a contract with American giant Pfizer to enroll over 10,000 bowel disorder patients. These people will help Pfizer study the genetic causes of diseases such as colitis or Crohn’s disease.
 
“I think that this illustrates how pharma companies are interested in the fact that we have a massive amount of information,” 23andMe's co-founder and chief executive Anne Wojcicki told Forbes.
 
“We have a very engaged consumer population, and these people want to participate in research. And we can do things much faster and more efficiently than any other research means in the world.”
 
From 23andMe's point of view, the revenue brought in by these major deals is much higher than the payments received from customers who buy the personal DNA testing kits. Just one of these deals can bring in twice as much money as all of the business's customer base. 

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Facebook
  • Google

Trending Articles

  • Victoria Beckham owed £350,000 by Harvey Nichols

  • M&G: FTSE 100 giant hits out at Rayner’s ground rent cap as it suffers loss

  • Fulham owner Khan sees his £1bn stadium construction project take next steps

  • John Lewis boss: UK economy facing a ‘permacrisis’ 

  • Don’t underestimate the free trade agreement Britain just joined

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Exclusive: Blackstone set to back AI ‘droid’ firm at $3.5bn valuation

    AI
    Blackstone skyscraper with modern architecture under clear blue sky, symbolizing financial power and urban development.
  • Mike Ashley’s Frasers snaps up Harvey Nichols 

    Retail
    Exterior view of the Harvey Nichols department store building facade with detailed windows and architectural columns
  • IT consultant ordered to pay £50,000 after being accused of stealing Soho House members’ personal details

    Legal
    Soho House has continued to attract new members to its clubs.
  • Experian Brings Personalised Credit Scores to ChatGPT in a UK First

    Business Wire
  • Lone Star Funds Completes Sale of Vigor Marine Group

    Business Wire
  • FTSE 100 Segro agrees to £14bn takeover by Prologis

    Property
    David Sleath, Chief Executive Officer, delivering a speech at a business conference with a focused expression.
  • Moody’s Brings Its Decision-Grade Intelligence to Gemini Enterprise for Financial Services

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook